Drug Trial Radar · NCT00163306
Efficacy of Pantoprazole in Patients Older Than 18 Years Who Have Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-339)
Last checked: Nov 19, 2026Latest source record: May 7, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,200
Actual
Start
May 2005
Primary completion
Not stated
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 14, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Gastroesophageal reflux disease (GERD) is a medical condition affecting the stomach and esophagus. GERD occurs when the lower esophageal sphincter does not close properly and stomach contents leaks back (refluxes) into the esophagus. GERD is one of the most common medical disorders, with estimates of up to 50% of adults reporting symptoms related to gastric reflux. Proton pump inhibitors (PPI) such as pantoprazole can relieve symptoms of GERD in a large proportion of patients. When refluxed stomach acidic content touches the lining of the esophagus, it causes a burning sensation in the chest or throat. This sensation is often referred to as heartburn. Some patients have symptoms of GERD without visible destruction of the tissue surface (no visible changes by endoscopic examination). The aim of the study is to evaluate the effect of pantoprazole on the complete remission of GERD. Complete remission is defined as endoscopically confirmed healing and symptom relief after a maximum of 12-week treatment period. Pantoprazole will be administered once daily in the morning. Endoscopy will be performed at the start of the study, and then as required after 4, 8, or 12 weeks. The study will provide further data on safety and tolerability of pantoprazole.
Conditions
- Gastroesophageal Reflux
Interventions
PantoprazoleDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- complete reflux disease remission rate after 8 weeks of treatment defined as symptom relief assessed by reflux questionnaire (ReQuest Trademark) and endoscopically confirmed healing.
Locations
79 sites in 4 countries. Site status is shown where the registry gives one.
Altana Pharma/Nycomed
Deutschlandsberg, Austria
Altana Pharma/Nycomed
Feldbach, Austria
Altana Pharma/Nycomed
Graz, Austria
Altana Pharma/Nycomed
Graz, Austria
Altana Pharma/Nycomed
Krems A. D. Donau, Austria
Altana Pharma/Nycomed
Lilienfeld, Austria
Altana Pharma/Nycomed
Stockerau, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Vienna, Austria
Altana Pharma/Nycomed
Wiener Neustadt, Austria
Altana Pharma/Nycomed
Amberg, Germany
Altana Pharma/Nycomed
Aschersleben, Germany
Altana Pharma/Nycomed
Bad Bramstedt, Germany
Altana Pharma/Nycomed
Bad Schwalbach, Germany
Altana Pharma/Nycomed
Beckum, Germany
Altana Pharma/Nycomed
Berlin, Germany
Altana Pharma/Nycomed
Berlin, Germany
Altana Pharma/Nycomed
Berlin, Germany
Altana Pharma/Nycomed
Flensburg, Germany
Altana Pharma/Nycomed
Freiburg im Breisgau, Germany
Altana Pharma/Nycomed
Freising, Germany
Altana Pharma/Nycomed
Germersheim, Germany
Altana Pharma/Nycomed
Hamburg, Germany
Altana Pharma/Nycomed
Haßfurt, Germany
Altana Pharma/Nycomed
Herzogenrath, Germany
Altana Pharma/Nycomed
Jülich, Germany
Altana Pharma/Nycomed
Kirchheimbolanden, Germany
Altana Pharma/Nycomed
Landsberg, Germany
Altana Pharma/Nycomed
Langen, Germany
Altana Pharma/Nycomed
Leipzig, Germany
Altana Pharma/Nycomed
Lübeck, Germany
Altana Pharma/Nycomed
Ludwigsburg, Germany
Altana Pharma/Nycomed
Ludwigshafen, Germany
Altana Pharma/Nycomed
Lütjenburg, Germany
Altana Pharma/Nycomed
Magdeburg, Germany
Altana Pharma/Nycomed
Magdeburg, Germany
Altana Pharma/Nycomed
Mönchengladbach, Germany
Altana Pharma/Nycomed
München, Germany
Altana Pharma/Nycomed
München, Germany
Showing 40 of 79 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.